Modality
siRNA
MOA
SGLT2i
Target
TNFα
Pathway
Proteasome
PsA
Development Pipeline
Preclinical
~May 2022
→ ~Aug 2023
Phase 1
~Nov 2023
→ ~Feb 2025
Phase 2
May 2025
→ Dec 2029
Phase 2Current
NCT07649156
137 pts·PsA
2025-05→2029-12·Recruiting
137 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-12-023.7y awayPh3 Readout· PsA
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2/3
Recruit…
Catalysts
Ph3 Readout
2029-12-02 · 3.7y away
PsA
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07649156 | Phase 2/3 | PsA | Recruiting | 137 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα |